Ultrasound-guided chest wall nerve blocks to reduce pain after minimally invasive coronary bypass surgery

Adults undergoing minimally invasive coronary artery bypass surgery (MIDCAB/MICS-CABG): combined interpectoral–pectoserratus plane block versus combined deep–superficial serratus anterior plane block versus standard analgesic management for postoperative pain (VAS) and recovery quality (QoR-40): a single-centre randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN32677289

Enrollment

180

Registered

2026-02-16

Start date

2023-07-03

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pain and recovery after minimally invasive coronary artery bypass surgery (MIDCAB/MICS-CABG) for coronary artery disease Signs and Symptoms

Interventions

This is a prospective, single-centre, randomised, parallel-group clinical trial (retrospectively registered

recruitment completed). Adult patients undergoing MIDCAB or MICS-CABG are randomised 1:1:1 using a predefined randomisation list generated by an investigator not involved in enrolment or outcome asses

15 mL injected between pectoralis major and pectoralis minor muscles (interpectoral plane) plus 15 mL injected between pectoralis minor and serratus anterior (pectoserratus plane). Group S (combined d

if pain persists despite this, dexketoprofen 50 mg is administered (tramadol dosing interval =4 hours). Outcomes are assessed during the hospital stay. Pain intensity is measured using VAS at 6, 12,

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age =18 years 2. Scheduled for minimally invasive coronary artery bypass surgery (MIDCAB or MICS-CABG) 3. Provided informed consent

Exclusion criteria

Exclusion criteria: 1. Known allergy to local anaesthetics 2. Chronic analgesic use 3. Coagulopathy 4. Infection at injection site 5. Peripheral neuropathy 6. Thoracic deformities

Countries

Türkiye

Contacts

Public ContactAlperen Kutay;Mesher Yildirim;Ensarioglu

;

alperenkutay.yildirim@sbu.edu.tr;mesher.ensarioglu@sbu.edu.tr+905366031176;+905465836148

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jun 29, 2026